CooperVision’s 4-year study results are promising for the company’s dual-focus myopia control 1-day soft contact lens in reducing the rate of progression of juvenile-onset myopia.
“Four-year results on the efficacy of our innovative myopia control lens represent a landmark in slowing myopia progression,” Paul Chamberlain, BSC(Hons), director of research programs for CooperVision, said in a press release from the company.
“The treatment is continuing to work for children who have been wearing MiSight contact lenses for the entire study, and their axial length progression in this last year has slowed further,” he continued. “This illustrates the benefits of beginning myopia management as early as possible to maximize the benefit.”
After the third year, myopia progression slowed in children wearing the MiSight contact lens: 59% as measured by mean cycloplegic spherical equivalent and 52% as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision daily disposable contact lens.
Researchers also found a significant reduction in myopic progression for the previous single vision 1-day wearers, showing that MiSight contact lenses are also effective when beginning myopia management at an older age.
CooperVision is presenting the multiyear study’s latest outcomes during the British Contact Lens Association Asia conference in Singapore this week.
MiSight 1-day contact lenses are currently available for sale in Canada, U.K., France, Spain, Portugal, The Netherlands, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight is not approved in the U.S.